TELA Bio (TELA) Gets a Buy from Piper Sandler

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on TELA Bio (TELA – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $4.94.

O’Brien covers the Healthcare sector, focusing on stocks such as Penumbra, Alphatec Holdings, and Boston Scientific. According to TipRanks, O’Brien has an average return of 6.4% and a 52.25% success rate on recommended stocks.

TELA Bio has an analyst consensus of Strong Buy, with a price target consensus of $13.25, a 168.22% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.

The company has a one-year high of $11.26 and a one-year low of $4.23. Currently, TELA Bio has an average volume of 154.1K.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TELA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TELA Bio (TELA) Company Description:

TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.